Abstract 64P
Background
KRAS is a frequent oncogene in human cancer and is an interesting therapeutic target due to its critical function in many malignancies. Although RAS was previously considered undruggable, recent successful identification of covalent inhibitors has shed light on the potential for cancer treatment. In drug research, RAS enzymatic activity is often measured, but methods based on RAS thermal stability (TSA) are also found useful. In these assays, RAS binding ligands stabilizes the structure over the native conformation and shifts its denaturation temperature. Among TSAs, differential scanning fluorimetry (DSF) has gained the most attention due to method’s good throughput. However, DSF lacks the needed sensitivity and results are markedly TSA dye-dependent. In addition, ligand behavior might vary when measured over the physiological temperature. In some cases, binding affinities obtained using isothermal chemical denaturation (ICD) have been found more reliable. Commonly used chemical denaturants like urea and guanidium chloride can be used to provide reliable information on ligand binding in a concentration dependent manner. However, these denaturants often require long incubation time and may affect the affinity of ionic compounds at high concentrations.
Methods
To overcome the difficulties in TSA and ICD techniques, we have developed a modification of the Protein-Probe (PP) technique, to measure isothermal protein stability at mild ICD conditions over time. The principle of this method is based on designed dual-labeled peptide-probe, and time-resolved Förster resonance energy transfer (TR-FRET) monitoring.
Results
As a model KRAS mutation, we studied KRAS(G12C) (50 nM) interaction with the most promising covalent inhibitors. Inhibitor induced stabilization of KRAS(G12C) can be monitored directly from the signals in a dose dependent manner in less than 60 min. The same effect was not seen with G12V.
Conclusions
ICD combined with the novel FRET-probe is a prominent option for TSAs, as no special equipment are needed. Isothermal concept can also potentially provide more understanding of how these proteins behave in vivo.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Academy of Finland and Otto A. Malm Foundation.
Disclosure
H. Härmä, K. Kopra: Financial Interests, Personal, Ownership Interest: QRET Technologies Oy. All other authors have declared no conflicts of interest.
Resources from the same session
62P - Anti-malarial drug quinacrine: A potential molecule for repurposing in targeting human non-small cell lung cancer cells (NSCLC)
Presenter: ANGSHUMAN SARKAR
Session: Cocktail & Poster Display session
Resources:
Abstract
63P - Role of EGFR-targeted therapy in the treatment of advanced and metastatic cervical cancers
Presenter: Abhishek Krishna
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Influence of efflux and uptake transporters on the pharmacokinetics of the SYK inhibitors entospletinib and lanraplenib
Presenter: Nancy Loos
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Targeting allosteric sites on PDK-1 and PLK-1 with bioactive compounds from <italic>Daucus carota</italic> as a potential therapy for triple-negative breast cancer
Presenter: Kayode Raheem
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
Presenter: Corinne Vannier
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - Investigating CDK4/6 palbociclib resistance mechanisms in MCF7 breast cancer cell line
Presenter: Heloise Beutier
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
Presenter: Sofija Jovanović Stojanov
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Molecular Tumor Board at the European Institute of Oncology: An early Italian precision oncology experience
Presenter: Edoardo Crimini
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - MDM alterations in patients with advanced or metastatic cancers
Presenter: Iwona Lugowska
Session: Cocktail & Poster Display session
Resources:
Abstract
73P - Automated detection of typical and atypical mitotic figures for improving survival prediction in breast cancer
Presenter: Saima Ben Hadj
Session: Cocktail & Poster Display session
Resources:
Abstract